Coherus BioSciences, Inc.
CHRS
$0.7818
-$0.0349-4.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -371.55% | 16.79% | -112.56% | 229.15% | -100.94% |
| Total Depreciation and Amortization | -33.31% | 30.50% | -21.23% | 41.77% | 18.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.58% | 411.73% | 98.00% | -345.74% | 371.54% |
| Change in Net Operating Assets | 188.64% | -182.85% | 752.70% | -278.65% | 123.06% |
| Cash from Operations | 146.13% | -203.82% | 227.73% | -261.49% | 76.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -100.00% | -78.70% | -- | -- |
| Other Investing Activities | -222.07% | 103.60% | -182.62% | -57.56% | -19.16% |
| Cash from Investing | -222.07% | -98.39% | -86.36% | 475.98% | -30.35% |
| Total Debt Issued | 100.00% | -100.38% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -64.79% | 101.80% | -92.25% |
| Repurchase of Common Stock | 0.00% | 99.42% | -129.66% | -128.53% | -86.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -100.04% | 22,039.76% | 16.58% | 5.24% |
| Cash from Financing | 238.32% | 99.91% | -21,286.58% | 142.35% | -96.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.83% | 38.59% | -164.08% | 593.20% | 207.88% |
